SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record-high vehicle deliveries for December and the fourth quarter, significantly surpassing previous figures and nearing one million cumulative vehicles. This strong performance, further supported by extended EV subsidies in China, is driving considerable community discussion and optimism about the company's path to profitability and its competitive standing in the electric vehicle market.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc. is trending following news of a strategic manufacturing partnership set to scale production of its drug screening reader for anticipated U.S. market entry. The community is actively discussing the stock's massive volume and micro-float, fueling excitement for potential short-squeeze-like parabolic gains. However, a recent private placement with lower-priced warrants has sparked debate among traders, creating a highly volatile environment with divided opinions on its immediate future.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is currently trending amidst significant investor confusion and frustration surrounding a recent dividend event and persistent tracking discrepancies with its underlying asset, SMCI. The community is actively questioning the ETF's unusual behavior, with some alleging it's a "scam" or facing an imminent reverse split, while others view the current downturn as a potential buying opportunity despite concerns about leveraged product decay.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is currently a hot topic, with community discussion centering on the ongoing delay and mixed initial data for its inhaled cystic fibrosis therapy, ARCT-032, which showed some mucus plug reduction but not significant lung function improvements. Investors are closely monitoring an active trade secret lawsuit against AbbVie, generating widespread hope for a substantial settlement or potential acquisition. Many believe the company's advanced mRNA platform and solid cash runway make the stock deeply undervalued amidst significant short interest.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Crypto is trending after a recent price surge ignited a polarized community discussion. Supporters emphasize its real-world utility through Flexa's merchant network and anticipate significant growth with pending regulatory clarity and strategic partnerships. However, many investors express deep frustration, warning of sustained manipulation and a history of pump-and-dump cycles despite its technological foundations.

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

SpaceX is trending due to widespread anticipation of a potential IPO in 2026, which is igniting significant speculative interest across the broader aerospace sector. Community discussions are heavily focused on identifying "SpaceX IPO plays," with companies like Momentus ($MNTS) gaining traction for its partnership on Falcon 9 missions and a notably low share count, sparking comparisons to past explosive meme stock surges.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust (GBTC) is trending amidst a fervent debate over Bitcoin's near-term price direction, with discussions highlighting recent ETF outflows and broader market dynamics. The community remains sharply divided, as many anticipate a "parabolic" rally for Bitcoin as a hedge against inflation, while others warn of an impending "crypto winter" and significant price corrections based on historical cycles and perceived lack of intrinsic value.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending amid intense community discussion following recent developments, including a partial summary judgment in its ongoing litigation and strategic changes to its executive team, which are fueling heightened speculation around a potential acquisition. Investors are closely monitoring progress for its rare disease therapy, MIPLYFFA, toward European market access and a patent term extension, while broadly criticizing management for perceived undervaluation and executive compensation. Despite these concerns, many maintain a bullish outlook, citing the company's significant cash reserves and pipeline assets as indicators of untapped value.

iShares Ethereum Trust (The) - Undivided Beneficial Interest

iShares Ethereum Trust ETF

iShares Ethereum Trust ETF ($ETHA) is trending amidst strong speculation surrounding spot Ethereum ETF approvals, particularly those offering staking, which is expected to drive institutional demand. The recent "Fusaka Upgrade" is also a key talking point, with its impact on Ethereum's burn rate fueling bullish outlooks and active options trading. While many investors are actively 'buying the dip' and positioning for a potential decoupling from Bitcoin, others maintain caution regarding crypto market volatility.

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is generating significant buzz after the FDA accepted its Biologics License Application for Veligrotug, granting Priority Review for Thyroid Eye Disease and setting a PDUFA target. The community is widely discussing Veligrotug's potential as a best-in-class treatment, citing its strong efficacy across both active and chronic TED compared to current therapies, which fuels analyst upgrades and M&A speculation for the company's innovative pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>Citi noted that while the company’s bookings jumped 85% in the third quarter, revenue was impacted by supply constraints and data center delays.</li><li>CoreWeave joined the DOE-backed Genesis Mission on Thursday.</li><li>It plans to make its purpose-built AI cloud platform available for advanced scientific workloads.</li></ul>CoreWeave Inc (CRWV) stock rose more than 17% on Friday amid Wall Street optimism and the company’s participation in the Department of Energy’s (DOE) Genesis Mission, which provides AI cloud support for scientific research.<a href="https://stocktwits.com/symbol/CRWV">CRWV</a> was among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">Citi Resumes Coverage</h2>Citi resumed coverage of the stock with a ‘Buy’ rating but cut its target price to $135 from $192, following a period of restriction, according to The Fly. This still represents a 70% upside from the current stock price of $79.Citi highlighted an 85% quarter-over-quarter surge in bookings in the third quarter, while noting that revenue was held back in the near term by supply constraints and delays in activating new power and data center capacity. The firm said demand remains strong and expects capacity to stay on track through the fourth quarter.<h2 class="st-heading-2">DOE’s Genesis Mission</h2>On Thursday, CoreWeave joined the Genesis Mission, a program that connects research institutions, supercomputing centers, and AI platforms to improve access to advanced computing resources and large-scale datasets.As part of the effort, CoreWeave plans to make its purpose-built AI cloud platform available for advanced scientific workloads.Earlier this year, the company launched CoreWeave Federal, a unit focused on providing secure AI cloud services to U.S. government agencies and defense partners. The platform is being prepared to meet federal requirements, including FedRAMP authorization, to support large-scale AI workloads.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits shifted to ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes. One user sounded bullish on the stock as they believe a double bottom pattern has been confirmed.<stembedurl>https://stocktwits.com/MomentusTradus/message/639688926</stembedurl>However, another user suggested a profit-booking opportunity.<stembedurl>https://stocktwits.com/Veechj/message/639688614</stembedurl>On Friday, CRWV stock recorded its biggest intraday gain since September 10. However, the stock has been under selling pressure lately, declining more than 36% over the past three months.CoreWeave operates 41 data centers, including eight that came online in the third quarter. The footprint represents about 90 megawatts of active power and roughly 2.9 gigawatts of contracted power, according to an S&amp;P report earlier this month.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/amicus-stock-surges-to-near-2-year-highs-on-bio-marin-s-4-8-b-buyout-deal/cLeiUBwREsk">Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of AI cloud-computing startup CoreWeave is displayed on a smartphone screen on May 16, 2025 in Suqian, Jiangsu Province of China. 

Why Did CoreWeave Stock Surge Over 17% Today?

Citi resumed coverage of the stock with a ‘Buy’ rating but cut its target price to $135 from $192.

Equity

<ul class="summary-bullets"><li>Ives expressed optimism that the technology capital expenditure “supercycle” will continue to drive the fourth industrial revolution over the next few years.</li><li>The analyst expects the tech bull market to have two more years of runway, stating that Wall Street is “underestimating” the AI-led boom in equities.</li><li>He called out bears, saying that they have never understood this tech AI-driven bull market since early 2023.</li></ul>Dan Ives, Global Head of Tech Research at Wedbush, on Wednesday clapped back at bears on Wall Street for voicing concerns about a potential “AI bubble.”In a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DivesTech/status/2001253857893212390">post</a> on X, Ives expressed optimism that the technology capital expenditure “supercycle” will continue to drive the fourth industrial revolution over the next few years.“We estimate trillions of spending the next few years and thus will keep this tech bull market thriving despite market fears,” he said.<figure class="image"><img style="aspect-ratio:726/250;" src="https://news.stocktwits-cdn.com/Dan_Ives_post_jpg_b4f0facbef.webp" alt="Dan Ives' post on X" width="726" height="250"><figcaption>Dan Ives' post on X | @divestech/X</figcaption></figure><h2 class="st-heading-2">Surging AI Capex</h2>BlackRock stated in its 2026 whitepaper that it expects AI capex to range between $5 trillion and $8 trillion globally by 2030. “The AI buildout could be faster and greater than all past technological revolutions,” the firm stated.The asset manager added that it sees AI capex supporting U.S. growth in 2026. It expects AI capital spending’s contribution to the economic growth of the U.S. to be three times its historical average next year.“This capital-intensive boost is likely to persist into next year, allowing growth to hold up even as the labor market keeps cooling,” it said.<h2 class="st-heading-2">Bull Market’s Legs</h2>Earlier, Ives said in a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DivesTech/status/1987108666592444848">post</a> on X that he expects the tech bull market to have two more years of runway.<figure class="image"><img style="aspect-ratio:727/167;" src="https://news.stocktwits-cdn.com/Dan_Ives_post_jpg_11d8aadb17.webp" alt="Dan Ives' post on X" width="727" height="167"><figcaption>Dan Ives' post on X | @divestech/X</figcaption></figure>In a separate post, Ives said bears have “NEVER understood this tech AI-driven bull market since early 2023.” He added that Wall Street is “underestimating” the boom in U.S. equities driven by AI.Meanwhile, U.S. equities declined in Wednesday’s opening trade. At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was down by 0.14%, the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust ETF</a> (QQQ) fell 0.36%, while the&nbsp;<a href="https://stocktwits.com/symbol/IYW">iShares US Technology ETF</a> (IYW) was down by 0.52%. Retail sentiment around the S&amp;P 500 ETF on Stocktwits was in the ‘bullish’ territory.<a href="https://stocktwits.com/symbol/NVDA">NVDA stock</a> is up 32% year-to-date and 35% in the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-terminates-6-5-billion-battery-deal-lg-energy-after-retreating-from-evs/cLeOWmAREpD">Ford Terminates $6.5 Billion LG Energy Deal After Retreating From EVs — And Retail Is Split</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dan Ives speaks at BTC, ETH and WLD are Friends on September 16, 2025 in Washington, DC.

Dan Ives Claps Back At ‘AI Bubble’ Bears, Says Tech Capex Supercycle Is Just Beginning

Ives stated that the trillions of dollars in capex over the next few years will keep the tech bull market intact.

Should You Invest in the iShares U.S. Technology ETF (IYW)?

 ETFs to Buy as Broadcom Trips 11% Despite Beating Q4 Earnings & Revenues

AVGO slid 11% after Q4 results despite beating on earnings and revenues, as concerns over AI margins weighed on sentiment, making ETFs like SMH a safer way to play the dip.

The Zacks Analyst Blog Highlights IYW, FTEC, AIQ, FDN, XT and BOTZ

AI-rich valuations spark caution, but strong Mag 7 earnings keep tech ETFs like IYW, FTEC, AIQ, FDN, XT and BOTZ in focus.

AI Valuations Rich, But Strong Earnings a Plus: ETFs in Focus

AI stocks stay elevated as FOMO drives momentum, but strong earnings ease bubble worries. Here's why risks remain -- and the ETFs best positioned to benefit.

Mag 7 Beats S&P 500 in Q3: Buy These 3 ETFs to Tap Their Strength

ETFs like XLG provide a diversified way to benefit from the Mag 7's Q3 earnings surge and the positive momentum expected going forward.

The Zacks Analyst Blog Highlights XLK, IYW, KNCT, RSPT, XSW, FITE and IGPT

XLK leads a volatile tech space as shoppers hunt value and undervalued ETFs like KNCT, RSPT and XSW draw attention after Black Friday softness.

3 Tech ETFs to Buy as AI Vanguard Palantir Plunges 19% in a Month

PLTR's 19% slide may spark interest in ETFs like XLK offering broader AI exposure and a buffer against lofty valuations.  

ETFs in Focus as AI Tools Boost Record Black Friday Spending

AI-fueled record Black Friday spending and soaring e-commerce traffic may lift AI-focused ETFs like IYW, AIQ, FDN, XT and BOTZ amid strong tech and online retail demand.

IYW
iShares US Technology ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IYW News

IYWiShares US Technology ETF